Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma

Omalizumab (Xolair) was approved by the U.S. Food and Drug Administration (FDA) on June 20, 2003, for subcutaneous (SC) treatment of adults and adolescents (aged 12 years and older) (a) who have moderate or severe persistent asthma, (b) who have a positive skin test or in vitro reactivity to a peren...

Descripción completa

Detalles Bibliográficos
Autor principal: Curtiss, Frederic R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2005
Materias:
Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437644/
https://www.ncbi.nlm.nih.gov/pubmed/16300422
http://dx.doi.org/10.18553/jmcp.2005.11.9.774
Descripción
Sumario:Omalizumab (Xolair) was approved by the U.S. Food and Drug Administration (FDA) on June 20, 2003, for subcutaneous (SC) treatment of adults and adolescents (aged 12 years and older) (a) who have moderate or severe persistent asthma, (b) who have a positive skin test or in vitro reactivity to a perennial aeroallergen, and (c) whose symptoms are inadequately controlled with inhaled corticosteroids. It is associated with off-label (unapproved use) for seasonal allergic rhinitis.

Ejemplares similares